Clinical phenotypes of asthma should link up with disease mechanisms

Current Opinion in Allergy and Clinical Immunology

Volumn 15, Issue 1, 2015, Pages 56-62

  Chung, Kian Fan ^a,b   Adcock, Ian M ^a,b  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Royal Brompton NIHR Biomedical Research Unit   (United Kingdom)

Author keywords

Neutrophilic asthma; sputum esoinophils; Th2 high

Indexed keywords

BIOLOGICAL MARKER; CORTICOSTEROID; CYTOKINE; PHARMACOLOGICAL BIOMARKER;

AIRWAY OBSTRUCTION; APOPTOSIS; ASTHMA; CLINICAL FEATURE; CLUSTER ANALYSIS; CORTICOSTEROID THERAPY; DISEASE SEVERITY; EOSINOPHILIA; GENE EXPRESSION; GENETIC PROCEDURES; HUMAN; INFLAMMATORY DISEASE; LUNG DISEASE; LUNG FUNCTION; MACROPHAGE; MICROARRAY ANALYSIS; ONSET AGE; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEOMICS; QUALITY OF LIFE; REVIEW; SPUTUM; SYSTEMS BIOLOGY; TH1 CELL; TRANSCRIPTOMICS; TREATMENT RESPONSE; ANIMAL; DESENSITIZATION; IMMUNOLOGY; METABOLISM; PROGNOSIS;

ANIMALS; ASTHMA; BIOLOGICAL MARKERS; BIOMARKERS, PHARMACOLOGICAL; CLUSTER ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; PHENOTYPE; PROGNOSIS;

EID: 84920873293     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000134     Document Type: Review

References (60)

1. Aplea to abandon asthma as a disease concept [editorial]. Lancet 2006; 368: 705.
2. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368:804-813.
3. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43:343-373.
4. Horn BR, Robin ED, Theodore J, Van Kessel A. Total eosinophil counts in the management of bronchial asthma. N Engl J Med 1975; 292:1152-1155.
5. Lee JJ, Jacobsen EA, McGarry MP, et al. Eosinophils in health and disease: the LIAR hypothesis. Clin Exp Allergy 2010; 40:563-575.
6. Chung KF. New treatments for severe treatment-resistant asthma: targeting the right patient. Lancet Respir Med 2013; 1:639-652.
7. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315-323.
8. Fitzpatrick AM, Teague WG, Meyers DA, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2011; 127:382-389, e1-13.
9. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-224.
10. Siroux V, Basagana X, Boudier A, et al. Identifying adult asthma phenotypes using a clustering approach. Eur Respir J 2011; 38:310-317.
11. Kim TB, Jang AS, Kwon HS, et al. Identification of asthma clusters in two independent Korean adultasthma cohorts.Eur Respir J 2013; 41:1308-1314.
12. Kaneko Y, Masuko H, Sakamoto T, et al. Asthma phenotypes in Japanese adults: their associations with the CCL5 and ADRB2 genotypes. Allergol Int 2013; 62:113-121.
13. Schatz M, Hsu JW, Zeiger RS, et al. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immunol 2014; 133:1549-1556.
14. Sutherland ER, Goleva E, King TS, et al. Cluster analysis of obesity and asthma phenotypes. PloS One 2012; 7:e36631.
15. Gibeon D, Batuwita K, Osmond M, et al. Obesity-associated severe asthma represents a distinct clinical phenotype: analysis of the British Thoracic Society Difficult Asthma Registry Patient cohort according to BMI. Chest 2013; 143:406-414.
16. Amelink M, de Nijs SB, de Groot JC, et al. Three phenotypes of adult-onset asthma. Allergy 2013; 68:674-680.
17. Deykin A, Lazarus SC, Fahy JV, et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. J Allergy Clin Immunol 2005; 115:720-727.
18. Moore WC, Hastie AT, Li X, et al. Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 2014; 133:1557-1563, e5.
19. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012; 185:612-619.
20. Jatakanon A, Uasuf C, Maziak W, et al. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160(5Pt1):1532-1539.
21. Schleich FN, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs. neutrophilic inflammation. BMC Pulmon Med 2013; 13:11.
22. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007; 104:15858-15863.
23. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180:388-395.
24. Peters MC, Mekonnen ZK, Yuan S, et al. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol 2014; 133:388-394.
25. Baines KJ, Simpson JL, Wood LG, et al. Transcriptional phenotypesof asthma defined by gene expression profiling of induced sputum samples. J Allergy Clin Immunol 2011; 127:153-160; 160.e1-9.
26. Baines KJ, Simpson JL, Wood LG, et al. Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes. J Allergy Clin Immunol 2014; 133:997-1007.
27. Israel E, Chervinsky PS, Friedman B, et al. Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 2002; 110:847-854.
28. Chaudhuri R, Livingston E, McMahon AD, et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med 2003; 168:1308-1311.
29. Sutherland ER, Goleva E, Strand M, et al. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008; 178:682-687.
30. Zhang Q, Illing R, Hui CK, et al. Bacteria in sputum of stable severe asthma and increased airway wall thickness. Respir Res 2012; 13:35.
31. Wood LG, Simpson JL, Hansbro PM, Gibson PG. Potentially pathogenic bacteria cultured from the sputum of stable asthmatics are associated with increased 8-isoprostane and airway neutrophilia. Free Radic Res 2010; 44:146-154.
32. Fitzpatrick AM, Holguin F, Teague WG, Brown LA. Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthma. J Allergy Clin Immunol 2008; 121:1372-1378; 1378.e1-3.
33. Huynh ML, Malcolm KC, Kotaru C, et al. Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med 2005; 172:972-979.
34. Nguyen LT, Lim S, Oates T, Chung KF. Increase in airway neutrophils after oral but not inhaled corticosteroid therapy in mild asthma. Respir Med 2005; 99:200-207.
35. Shannon J, Ernst P, Yamauchi Y, et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008; 133:420-426.
36. Wysocki K, Park SY, Bleecker E, et al. Characterization of factors associated with systemic corticosteroid use in severe asthma: Data from the Severe Asthma Research Program. J Allergy Clin Immunol 2014; 133:915-918.
37. Chang PJ, Bhavsar PK, Michaeloudes C, et al. Corticosteroid insensitivity of chemokine expression in airway smooth muscle of patients with severe asthma. J Allergy Clin Immunol 2012; 130:877-885, e5.
38. Bhavsar P, Khorasani N, Hew M, et al. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J 2010; 35:750-756.
39. Ito K, Lim S, Caramori G, et al. Cigarette smoking reduces histone deace-tylase 2 expression, enhances cytokine expression, and inhibits glucocorti-coid actions in alveolar macrophages. FASEB J 2001; 15:1110-1112.
40. Irusen E, Matthews JG, Takahashi A, et al. p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 2002; 109:649-657.
41. Leung DYM, Hamid Q, Vottero A, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997; 186:1567-1574.
42. Gibeon D, Chung KF. The investigation of severe asthma to define pheno-types. Clin Exp Allergy 2012; 42:678-692.
43. Hanania NA, Wenzel S, Rosen K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187:804-811.
44. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651-659.
45. Ortega H, Li H, Suruki R, et al. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma. Ann Am Thorac Soc 2014; 11:1011-1017.
46. Wenzel SE, Wang L, Pirozzi G. Dupilumab in persistent asthma. N Engl J Med 2013; 369:1276.
47. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365:1088-1098.
48. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011; 184:602-615.
49. Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012; 130:647-654, e10.
50. Kanemitsu Y, Matsumoto H, Izuhara K, et al. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013; 132:305-312, e3.
51. Nagasaki T, Matsumoto H, Kanemitsu Y, et al. Integrating longitudinal information on pulmonary function and inflammation using asthma phenotypes. J Allergy Clin Immunol 2014; 133:1474-1477; 1477.e1-2.
52. Saito J, Zhang Q, Hui C, et al. Sputum hydrogen sulfide as a novel biomarker of obstructive neutrophilic asthma. J Allergy Clin Immunol 2013; 131:232-234, e1-3.
53. Kabesch M, Adcock IM. Epigenetics in asthma and COPD. Biochimie 2012; 94:2231-2241.
54. Tsitsiou E, Williams AE, Moschos SA, et al. Transcriptome analysis shows activation of circulating CD8+ T cells in patients with severe asthma. J Allergy Clin Immunol 2012; 129:95-103.
55. O'Neil SE, Sitkauskiene B, Babusyte A, et al. Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment. Respir Res 2011; 12:124.
56. Hwang S, Son SW, Kim SC, et al. A protein interaction network associated with asthma. J Theor Biol 2008; 252:722-731.
57. Auffray C, Adcock IM, Chung KF, et al. An integrative systems biology approach to understanding pulmonary diseases. Chest 2010; 137:1410-1416.
58. Chen R, Snyder M. Systems biology: personalized medicine for the future? Curr Opin Pharmacol 2012; 12:623-628.
59. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of sub-clonal mutations in chronic lymphocytic leukemia. Cell 2013; 152:714-726.
60. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010; 363:301-304.